12805474	43	Terry AV Jr	The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development.	The Journal of pharmacology and experimental therapeutics	2003	97
18672400	43	Lannfelt L	Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.	The Lancet. Neurology	2008	109
12089448	100	Aiuti A	Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.	Science	2002	219
15032591	100	Buckley RH	Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution.	Annual review of immunology	2004	102
21734253	100	Bachmann V	Functional ADA polymorphism increases sleep depth and reduces vigilant attention in humans.	Cerebral cortex	2012	33
11171943	142	Cuzzocrea S	Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury.	Pharmacological reviews	2001	127
12716823	142	Ceriello A	New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy.	Diabetes care	2003	117
21208101	142	O'Shaughnessy J	Iniparib plus chemotherapy in metastatic triple-negative breast cancer.	The New England journal of medicine	2011	180
21862407	142	Gelmon KA	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.	The Lancet. Oncology	2011	225
24997452	142	Varga ZV	Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.	Biochimica et biophysica acta	2015	31
26091343	142	Bai P	Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance.	Molecular cell	2015	21
27002934	142	Drew Y	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.	British journal of cancer	2016	15
17569696	196	Okey AB	An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI.	Toxicological sciences 	2007	60
18174953	196	Bonefeld-Jørgensen EC	Endocrine-disrupting potential of bisphenol A, bisphenol A dimethacrylate, 4-n-nonylphenol, and 4-n-octylphenol in vitro: new data and a brief review.	Environmental health perspectives	2007	69
18281716	196	Hotchkiss AK	Fifteen years after "Wingspread"--environmental endocrine disrupters and human and wildlife health: where we are today and where we need to go.	Toxicological sciences 	2008	54
18817753	196	Puga A	The aryl hydrocarbon receptor cross-talks with multiple signal transduction pathways.	Biochemical pharmacology	2009	85
21488901	196	Weiner HL	Oral tolerance.	Immunological reviews	2011	153
21908767	196	Denison MS	Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor.	Toxicological sciences 	2011	126
21976023	196	Opitz CA	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.	Nature	2011	244
22166497	196	McHale CM	Current understanding of the mechanism of benzene-induced leukemia in humans: implications for risk assessment.	Carcinogenesis	2012	34
22262711	196	Kim MJ	Inflammatory pathway genes belong to major targets of persistent organic pollutants in adipose cells.	Environmental health perspectives	2012	31
16622124	207	Yaguchi S	Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor.	Journal of the National Cancer Institute	2006	66
17203200	207	Chong ZZ	The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection.	International journal of molecular medicine	2007	56
17267664	207	Bolan EA	D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.	Molecular pharmacology	2007	63
17353198	207	Ji Z	Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells.	The Journal of biological chemistry	2007	98
18324353	207	Hatcher H	Curcumin: from ancient medicine to current clinical trials.	Cellular and molecular life sciences 	2008	230
19195051	207	Fabregat I	Dysregulation of apoptosis in hepatocellular carcinoma cells.	World journal of gastroenterology	2009	60
19298854	207	Sarkar FH	Cellular signaling perturbation by natural products.	Cellular signalling	2009	53
19713527	207	Yang WL	The E3 ligase TRAF6 regulates Akt ubiquitination and activation.	Science	2009	161
20639898	207	Whittaker S	The role of signaling pathways in the development and treatment of hepatocellular carcinoma.	Oncogene	2010	190
20671809	207	Martelli AM	The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.	Oncotarget	2010	67
21430222	207	Brown GT	Lipopolysaccharide signaling without a nucleus: kinase cascades stimulate platelet shedding of proinflammatory IL-1β-rich microparticles.	Journal of immunology	2011	41
21974986	207	Otvos L Jr	Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.	BMC biotechnology	2011	36
22586279	207	Chokshi A	Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure.	Circulation	2012	49
22817723	207	O'Neill C	Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease.	Biochemical Society transactions	2012	33
25173700	207	Heras-Sandoval D	The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration.	Cellular signalling	2014	63
25284585	207	Dillon LM	P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.	Oncogene	2015	17
25317149	207	Maiese K	Driving neural regeneration through the mammalian target of rapamycin.	Neural regeneration research	2014	23
25796440	207	Paw I	Mechanisms regulating glioma invasion.	Cancer letters	2015	31
26451606	207	Sharma N	PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth.	Oncotarget	2015	33
27061150	207	Kim H	Mango polyphenolics reduce inflammation in intestinal colitis-involvement of the miR-126/PI3K/AKT/mTOR axis in vitro and in vivo.	Molecular carcinogenesis	2017	5
16771591	308	Wörle-Knirsch JM	Oops they did it again! Carbon nanotubes hoax scientists in viability assays.	Nano letters	2006	118
2659990	351	Stevens DL	Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A.	The New England journal of medicine	1989	176
12702875	351	Kayed R	Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.	Science	2003	950
14676042	351	Ritchie CW	Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.	Archives of neurology	2003	146
15864339	351	Gandy S	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.	The Journal of clinical investigation	2005	101
16738244	351	Deshpande A	Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons.	The Journal of neuroscience 	2006	115
19581601	351	Britschgi M	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.	Proceedings of the National Academy of Sciences of the United States of America	2009	46
19951690	351	Sun B	Imbalance between GABAergic and Glutamatergic Transmission Impairs Adult Neurogenesis in an Animal Model of Alzheimer's Disease.	Cell stem cell	2009	49
8599934	387	Lang P	Protein kinase A phosphorylation of RhoA mediates the morphological and functional effects of cyclic AMP in cytotoxic lymphocytes.	The EMBO journal	1996	123
10224076	387	Benard V	Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases.	The Journal of biological chemistry	1999	213
10328216	387	Fritz G	Rho GTPases are over-expressed in human tumors.	International journal of cancer	1999	166
12869558	590	Nicolet Y	Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products.	The Journal of biological chemistry	2003	85
17706760	590	Eddleston M	Management of acute organophosphorus pesticide poisoning.	Lancet	2008	77
18726789	590	Eaton DL	Review of the toxicology of chlorpyrifos with an emphasis on human exposure and neurodevelopment.	Critical reviews in toxicology	2008	66
21182866	590	Rohlman DS	Correlating neurobehavioral performance with biomarkers of organophosphorous pesticide exposure.	Neurotoxicology	2011	36
20823850	673	Bollag G	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.	Nature	2010	428
21639808	673	Chapman PB	Improved survival with vemurafenib in melanoma with BRAF V600E mutation.	The New England journal of medicine	2011	1498
25891304	673	Postow MA	Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.	The New England journal of medicine	2015	330
7890387	820	Larrick JW	Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein.	Infection and immunity	1995	117
12244186	820	Scott MG	The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses.	Journal of immunology	2002	122
15067080	820	Elssner A	A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release.	Journal of immunology	2004	97
16030233	820	Tzeng YL	Cationic antimicrobial peptide resistance in Neisseria meningitidis.	Journal of bacteriology	2005	70
16293630	820	Rosenfeld Y	Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action.	The Journal of biological chemistry	2006	63
16456005	820	Mookherjee N	Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37.	Journal of immunology	2006	106
16716248	820	Dürr UH	LL-37, the only human member of the cathelicidin family of antimicrobial peptides.	Biochimica et biophysica acta	2006	158
18818205	820	Wang G	Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles.	The Journal of biological chemistry	2008	69
19710683	820	Cogen AL	Selective antimicrobial action is provided by phenol-soluble modulins derived from Staphylococcus epidermidis, a normal resident of the skin.	The Journal of investigative dermatology	2010	80
23267025	820	Kahlenberg JM	Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages.	Journal of immunology	2013	51
26556394	820	Xhindoli D	The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator.	Biochimica et biophysica acta	2016	16
10562656	847	Winkler BS	Oxidative damage and age-related macular degeneration.	Molecular vision	1999	137
21321970	847	Jomova K	Arsenic: toxicity, oxidative stress and human disease.	Journal of applied toxicology 	2011	81
3299090	920	Richman DD	The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.	The New England journal of medicine	1987	195
7675046	920	Walter EA	Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.	The New England journal of medicine	1995	327
7935654	920	Connor EM	Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.	The New England journal of medicine	1994	399
12491162	920	Sacktor N	The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy.	Journal of neurovirology	2002	109
16319381	920	Severe P	Antiretroviral therapy in a thousand patients with AIDS in Haiti.	The New England journal of medicine	2005	99
18382686	920	Funderburg N	Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis.	PloS one	2008	60
18480202	920	Riddler SA	Class-sparing regimens for initial treatment of HIV-1 infection.	The New England journal of medicine	2008	191
19265479	920	Jiang W	Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.	The Journal of infectious diseases	2009	236
20004464	920	DART Trial Team.	Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.	Lancet	2010	126
20108382	920	Lawn SD	Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease.	AIDS	2009	81
20371685	920	Grossman SA	Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.	Clinical cancer research 	2010	129
21471244	920	Xing S	Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.	Journal of virology	2011	79
21690475	920	Slingluff CL Jr	Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine.	Journal of clinical oncology 	2011	37
21725250	920	Byrd DA	Neurocognitive impact of substance use in HIV infection.	Journal of acquired immune deficiency syndromes	2011	46
21831714	920	Laurent C	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.	The Lancet. Infectious diseases	2011	38
22362849	920	Peter JG	Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.	The European respiratory journal	2012	53
22820792	920	Thompson MA	Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel.	JAMA	2012	262
23065532	920	Kalichman SC	Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs.	Journal of general internal medicine	2013	34
24185941	920	Krishnan S	Evidence for innate immune system activation in HIV type 1-infected elite controllers.	The Journal of infectious diseases	2014	40
24675585	920	Nakiyingi L	Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.	Journal of acquired immune deficiency syndromes	2014	31
17332326	1026	Li M	Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.	Cancer research	2007	67
18171934	1026	Langley B	Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.	The Journal of neuroscience 	2008	61
22108298	1026	Piotrowska H	Biological activity of piceatannol: leaving the shadow of resveratrol.	Mutation research	2012	41
10529352	1080	Holland IB	ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans.	Journal of molecular biology	1999	117
17466744	1080	Witt H	Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy.	Gastroenterology	2007	91
15858066	1137	Hurst RS	A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization.	The Journal of neuroscience 	2005	138
17825262	1137	Grady SR	The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum.	Biochemical pharmacology	2007	105
19023041	1137	Buccafusco JJ	Desensitization of nicotinic acetylcholine receptors as a strategy for drug development.	The Journal of pharmacology and experimental therapeutics	2009	50
19126755	1137	Albuquerque EX	Mammalian nicotinic acetylcholine receptors: from structure to function.	Physiological reviews	2009	366
11809184	1234	Fellay J	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.	Lancet	2002	82
21813459	1234	Mussolino C	A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity.	Nucleic acids research	2011	227
26499806	1244	Chen Z	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade.	Cancer letters	2016	26
26756674	1244	Bhise NS	A liver-on-a-chip platform with bioprinted hepatic spheroids.	Biofabrication	2016	20
7565624	1268	Felder CC	Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.	Molecular pharmacology	1995	139
8819477	1268	Showalter VM	Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.	The Journal of pharmacology and experimental therapeutics	1996	127
9204917	1268	Glass M	Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.	The Journal of neuroscience 	1997	116
15229230	1268	Lichtman AH	Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity.	The Journal of pharmacology and experimental therapeutics	2004	110
21525939	1268	Donadelli M	Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.	Cell death and disease	2011	41
24633558	1268	Battistella G	Long-term effects of cannabis on brain structure.	Neuropsychopharmacology 	2014	31
25220897	1268	Castaneto MS	Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.	Drug and alcohol dependence	2014	38
18256376	1401	Szeto CC	Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients.	Clinical journal of the American Society of Nephrology 	2008	52
19324974	1401	Shyamsundar M	Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.	American journal of respiratory and critical care medicine	2009	56
20016471	1401	Barreto DV	Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease.	Kidney international	2010	51
21252259	1401	Sandler NG	Plasma levels of soluble CD14 independently predict mortality in HIV infection.	The Journal of infectious diseases	2011	346
22752869	1401	Eyre DW	Predictors of first recurrence of Clostridium difficile infection: implications for initial management.	Clinical infectious diseases 	2012	34
25761863	1401	Michelena J	Systemic inflammatory response and serum lipopolysaccharide levels predict multiple organ failure and death in alcoholic hepatitis.	Hepatology	2015	26
26020495	1401	Waschki B	Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease.	American journal of respiratory and critical care medicine	2015	22
26065825	1401	Haapakoski R	Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.	Brain, behavior, and immunity	2015	28
7535770	1432	Raingeaud J	Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine.	The Journal of biological chemistry	1995	395
9069290	1432	Han J	Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation.	Nature	1997	165
10604986	1432	Kol A	Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells.	Journal of immunology	2000	102
12509443	1432	Frevel MA	p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts.	Molecular and cellular biology	2003	91
15256590	1432	Huffman DL	Mitogen-activated protein kinase pathways defend against bacterial pore-forming toxins.	Proceedings of the National Academy of Sciences of the United States of America	2004	113
16402404	1432	Sadeghi K	Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns.	European journal of immunology	2006	100
17170118	1432	Sun L	Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA.	The Journal of biological chemistry	2007	69
17392283	1432	Medvedev AE	Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance.	The Journal of biological chemistry	2007	61
18492738	1432	Bhavsar P	Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma.	Thorax	2008	63
18846208	1432	Bischof LJ	Activation of the unfolded protein response is required for defenses against bacterial pore-forming toxin in vivo.	PLoS pathogens	2008	71
20110572	1432	Schwartz EA	Nutrient modification of the innate immune response: a novel mechanism by which saturated fatty acids greatly amplify monocyte inflammation.	Arteriosclerosis, thrombosis, and vascular biology	2010	42
21205892	1432	Adachi K	T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	36
22395444	1432	Sharma V	Zinc oxide nanoparticles induce oxidative DNA damage and ROS-triggered mitochondria mediated apoptosis in human liver cells (HepG2).	Apoptosis 	2012	46
23272696	1432	Wu J	Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-Oxozeaenol.	ACS chemical biology	2013	26
26320263	1432	Carestia A	Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets.	Journal of leukocyte biology	2016	13
1940799	1437	de Waal Malefyt R	Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes.	The Journal of experimental medicine	1991	645
7629501	1437	Sallusto F	Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.	The Journal of experimental medicine	1995	427
8274730	1437	Tilg H	Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.	Blood	1994	127
12952922	1437	Doran KS	Group B streptococcal beta-hemolysin/cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis.	The Journal of clinical investigation	2003	76
17492620	1437	Dubsky P	IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL.	European journal of immunology	2007	57
18287062	1437	Hodi FS	Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients.	Proceedings of the National Academy of Sciences of the United States of America	2008	171
19666104	1437	Enstrom AM	Differential monocyte responses to TLR ligands in children with autism spectrum disorders.	Brain, behavior, and immunity	2010	73
20833247	1437	Ashwood P	Altered T cell responses in children with autism.	Brain, behavior, and immunity	2011	60
22822024	1437	Leentjens J	Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.	American journal of respiratory and critical care medicine	2012	32
24954781	1437	Middleton G	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.	The Lancet. Oncology	2014	45
18426988	1440	Devine SM	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.	Blood	2008	72
19161986	1440	De Clercq E	The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).	Biochemical pharmacology	2009	55
20007560	1440	Hsieh MM	Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.	The New England journal of medicine	2009	79
12370347	1493	Zheng SG	Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors.	Journal of immunology	2002	110
17293384	1493	Czerniecki BJ	Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.	Cancer research	2007	79
22326924	1493	Madan RA	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2012	92
24445516	1493	Gangadhar TC	Mitigating the toxic effects of anticancer immunotherapy.	Nature reviews. Clinical oncology	2014	32
25795410	1493	Weber JS	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.	The Lancet. Oncology	2015	227
27410923	1493	Davids MS	Ipilimumab for Patients with Relapse after Allogeneic Transplantation.	The New England journal of medicine	2016	23
16112414	1543	Tsuchiya Y	Cytochrome P450-mediated metabolism of estrogens and its regulation in human.	Cancer letters	2005	90
19054769	1543	Wincent E	The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo3,2-bcarbazole is present in humans.	The Journal of biological chemistry	2009	55
20000589	1543	Schroeder JC	The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor.	Biochemistry	2010	47
20106948	1543	DiNatale BC	Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling.	Toxicological sciences 	2010	98
17241619	1544	Guillouzo A	The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.	Chemico-biological interactions	2007	61
18160535	1544	Lee MY	Three-dimensional cellular microarray for high-throughput toxicology assays.	Proceedings of the National Academy of Sciences of the United States of America	2008	66
19651758	1544	Fisher CD	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.	Drug metabolism and disposition	2009	63
19877180	1544	Sullivan GJ	Generation of functional human hepatic endoderm from human induced pluripotent stem cells.	Hepatology	2010	110
11961061	1548	Dempsey D	Accelerated metabolism of nicotine and cotinine in pregnant smokers.	The Journal of pharmacology and experimental therapeutics	2002	97
19279561	1548	Ho MK	Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.	Clinical pharmacology and therapeutics	2009	59
8035341	1555	Shimada T	Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians.	The Journal of pharmacology and experimental therapeutics	1994	224
10037683	1555	Sueyoshi T	The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene.	The Journal of biological chemistry	1999	124
15063083	1555	Ingelman-Sundberg M	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.	Trends in pharmacological sciences	2004	70
16373351	1555	Zhao Y	Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.	The Journal of biological chemistry	2006	62
16584116	1555	Guengerich FP	Cytochrome P450s and other enzymes in drug metabolism and toxicity.	The AAPS journal	2006	78
20538623	1555	Yang X	Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.	Genome research	2010	69
21505298	1555	Yuan J	Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.	AIDS	2011	38
27039104	1555	Heslop JA	Mechanistic evaluation of primary human hepatocyte culture using global proteomic analysis reveals a selective dedifferentiation profile.	Archives of toxicology	2017	6
19902987	1565	Zhou SF	Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.	Clinical pharmacokinetics	2009	49
20385997	1565	Dezentjé VO	Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.	Journal of clinical oncology 	2010	44
24060820	1565	Province MA	CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.	Clinical pharmacology and therapeutics	2014	33
14744237	1571	Caro AA	Oxidative stress, toxicology, and pharmacology of CYP2E1.	Annual review of pharmacology and toxicology	2004	81
16608838	1576	Gu X	Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents.	The Journal of biological chemistry	2006	80
18268015	1576	Takagi S	Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4.	The Journal of biological chemistry	2008	65
22015057	1576	Garcia-Donas J	Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.	The Lancet. Oncology	2011	60
7680764	1649	Fisher RI	Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.	The New England journal of medicine	1993	164
10931302	1649	Swords WE	Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor.	Molecular microbiology	2000	99
18005243	1649	Lee SY	Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells.	Cellular microbiology	2008	54
18226581	1649	Pfreundschuh M	Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).	The Lancet. Oncology	2008	138
22718839	1649	Delarue R	CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.	Blood	2013	40
22873532	1649	Kluin-Nelemans HC	Treatment of older patients with mantle-cell lymphoma.	The New England journal of medicine	2012	52
23375551	1649	Martelli M	Diffuse large B-cell lymphoma.	Critical reviews in oncology/hematology	2013	42
23578722	1649	Delarue R	Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial.	The Lancet. Oncology	2013	26
18981090	1728	Rushworth SA	Lipopolysaccharide-induced expression of NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive inflammatory responses in human monocytes.	Journal of immunology	2008	50
20805291	1728	Hardwick RN	Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease.	Drug metabolism and disposition	2010	48
21289251	1728	Ghanim H	A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal.	The Journal of clinical endocrinology and metabolism	2011	39
18786299	1803	DeFronzo RA	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.	Current medical research and opinion	2008	82
20580422	1803	Bergenstal RM	Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.	Lancet	2010	126
21208359	1803	Madsbad S	An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.	Diabetes, obesity and metabolism	2011	36
21334333	1803	Elashoff M	Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.	Gastroenterology	2011	127
22471248	1803	Deacon CF	Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.	Diabetes, obesity and metabolism	2012	32
22843705	1803	Kröller-Schön S	Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.	Cardiovascular research	2012	37
23440284	1803	Singh S	Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.	JAMA internal medicine	2013	61
9041202	1956	Relf M	Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.	Cancer research	1997	128
15269313	1956	Cunningham D	Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.	The New England journal of medicine	2004	891
16014882	1956	Shepherd FA	Erlotinib in previously treated non-small-cell lung cancer.	The New England journal of medicine	2005	1010
16467544	1956	Bonner JA	Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.	The New England journal of medicine	2006	811
17192538	1956	Geyer CE	Lapatinib plus capecitabine for HER2-positive advanced breast cancer.	The New England journal of medicine	2006	587
18403491	1956	Sampson JH	Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.	Neuro-oncology	2008	54
19027483	1956	Kim ES	Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.	Lancet	2008	258
19201650	1956	Cohen EE	Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.	The Lancet. Oncology	2009	52
19692684	1956	Rosell R	Screening for epidermal growth factor receptor mutations in lung cancer.	The New England journal of medicine	2009	452
20573926	1956	Maemondo M	Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.	The New England journal of medicine	2010	979
21641636	1956	Maughan TS	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.	Lancet	2011	199
21783417	1956	Zhou C	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.	The Lancet. Oncology	2011	709
23883922	1956	Garassino MC	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.	The Lancet. Oncology	2013	116
24439929	1956	Wu YL	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2014	223
24831979	1956	Gregorc V	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.	The Lancet. Oncology	2014	39
24867380	1956	Liu S	Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms.	Cancer treatment reviews	2014	28
25923549	1956	Jänne PA	AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.	The New England journal of medicine	2015	228
25923550	1956	Sequist LV	Rociletinib in EGFR-mutated non-small-cell lung cancer.	The New England journal of medicine	2015	125
26045340	1956	Thatcher N	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.	The Lancet. Oncology	2015	52
26727163	1956	Quoix E	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.	The Lancet. Oncology	2016	17
11756984	2054	Friedrich AW	Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms.	The Journal of infectious diseases	2002	202
17085726	2054	Gyles CL	Shiga toxin-producing Escherichia coli: an overview.	Journal of animal science	2007	145
21199911	2054	Fuller CA	Shiga toxin subtypes display dramatic differences in potency.	Infection and immunity	2011	54
21291586	2054	Käppeli U	Human infections with non-O157 Shiga toxin-producing Escherichia coli, Switzerland, 2000-2009.	Emerging infectious diseases	2011	39
22289607	2054	Beutin L	Outbreak of Shiga toxin-producing Escherichia coli (STEC) O104:H4 infection in Germany causes a paradigm shift with regard to human pathogenicity of STEC strains.	Journal of food protection	2012	46
22760050	2054	Scheutz F	Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature.	Journal of clinical microbiology	2012	142
15616603	2064	Urban-Klein B	RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.	Gene therapy	2005	106
18288997	2064	Petrelli A	From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.	Current medicinal chemistry	2008	67
18375893	2064	Seidman AD	Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.	Journal of clinical oncology 	2008	117
19179558	2064	Blackwell KL	Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.	Annals of oncology 	2009	48
20371474	2064	Amin DN	Resiliency and vulnerability in the HER2-HER3 tumorigenic driver.	Science translational medicine	2010	63
21991949	2064	Slamon D	Adjuvant trastuzumab in HER2-positive breast cancer.	The New England journal of medicine	2011	356
22149875	2064	Baselga J	Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.	The New England journal of medicine	2012	394
22276820	2064	von Minckwitz G	Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.	The New England journal of medicine	2012	94
22276821	2064	Bear HD	Bevacizumab added to neoadjuvant chemotherapy for breast cancer.	The New England journal of medicine	2012	94
22967996	2064	Awada A	Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.	Annals of oncology 	2013	26
23102520	2064	Cervantes A	Current questions for the treatment of advanced gastric cancer.	Cancer treatment reviews	2013	32
23122784	2064	Bachelot T	Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.	The Lancet. Oncology	2013	72
24095300	2064	Robidoux A	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.	The Lancet. Oncology	2013	54
24239210	2064	Buzdar AU	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.	The Lancet. Oncology	2013	27
24473399	2064	Kurokawa Y	Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1).	British journal of cancer	2014	23
24794243	2064	von Minckwitz G	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.	The Lancet. Oncology	2014	77
25358515	2064	Polzer B	Molecular profiling of single circulating tumor cells with diagnostic intention.	EMBO molecular medicine	2014	45
22028871	2078	Schaaf S	Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology.	PloS one	2011	77
25730763	2078	Cooper CS	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue.	Nature genetics	2015	51
9751507	2099	Kuiper GG	Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.	Endocrinology	1998	566
15014181	2099	Coombes RC	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.	The New England journal of medicine	2004	259
15084758	2099	Mueller SO	Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor alpha (ERalpha) and ERbeta in human cells.	Toxicological sciences 	2004	80
20519679	2099	Swain SM	Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer.	The New England journal of medicine	2010	57
22949852	2099	Singh S	Epigenetic effects of environmental chemicals bisphenol A and phthalates.	International journal of molecular sciences	2012	43
23965901	2099	Gucalp A	Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.	Clinical cancer research 	2013	86
19220204	2147	Vanhoutte PM	Endothelial dysfunction and vascular disease.	Acta physiologica	2009	122
26559317	2147	Siegal DM	Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.	The New England journal of medicine	2015	63
24864123	2152	Sandler NG	Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection.	The Journal of infectious diseases	2014	24
8127021	2335	Ryan MJ	HK-2: an immortalized proximal tubule epithelial cell line from normal adult human kidney.	Kidney international	1994	155
14536091	2335	de la Mata M	A slow RNA polymerase II affects alternative splicing in vivo.	Molecular cell	2003	228
18753317	2335	Rowlands AS	Directing osteogenic and myogenic differentiation of MSCs: interplay of stiffness and adhesive ligand presentation.	American journal of physiology. Cell physiology	2008	92
8770536	2353	Hayes JD	The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance.	Critical reviews in biochemistry and molecular biology	1995	463
11018583	2353	Evans AR	Going APE over ref-1.	Mutation research	2000	167
11257452	2353	Guha M	LPS induction of gene expression in human monocytes.	Cellular signalling	2001	369
14607893	2353	Agrawal S	Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos.	Journal of immunology	2003	189
15090535	2353	Maggiolini M	The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.	The Journal of biological chemistry	2004	121
20139302	2353	Raha D	Close association of RNA polymerase II and many transcription factors with Pol III genes.	Proceedings of the National Academy of Sciences of the United States of America	2010	90
22649253	2353	Raineki C	Effects of early-life abuse differ across development: infant social behavior deficits are followed by adolescent depressive-like behaviors mediated by the amygdala.	The Journal of neuroscience 	2012	53
7822316	2475	Sabers CJ	Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells.	The Journal of biological chemistry	1995	171
16012795	2475	Chang SM	Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.	Investigational new drugs	2005	89
16186256	2475	Sarkar S	Lithium induces autophagy by inhibiting inositol monophosphatase.	The Journal of cell biology	2005	243
17360675	2475	Urano J	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells.	Proceedings of the National Academy of Sciences of the United States of America	2007	62
17921520	2475	Sarkar S	A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.	Human molecular genetics	2008	87
18391949	2475	Williams A	Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.	Nature chemical biology	2008	207
18848473	2475	Weichhart T	The TSC-mTOR signaling pathway regulates the innate inflammatory response.	Immunity	2008	184
19471118	2475	Demidenko ZN	At concentrations that inhibit mTOR, resveratrol suppresses cellular senescence.	Cell cycle	2009	51
19771169	2475	Balgi AD	Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.	PloS one	2009	108
20089925	2475	Malagelada C	Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.	The Journal of neuroscience 	2010	103
20335217	2475	Turnquist HR	mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.	Blood	2010	45
20659474	2475	Ding WX	Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice.	Gastroenterology	2010	130
22098780	2475	Khan MI	Induction of ROS, mitochondrial damage and autophagy in lung epithelial cancer cells by iron oxide nanoparticles.	Biomaterials	2012	44
22287548	2475	Chen W	Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway.	Cancer research	2012	31
22357447	2475	Markman B	Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.	Annals of oncology 	2012	40
22778315	2475	Busaidy NL	Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.	Journal of clinical oncology 	2012	40
22919032	2475	McInturff AM	Mammalian target of rapamycin regulates neutrophil extracellular trap formation via induction of hypoxia-inducible factor 1 α.	Blood	2012	43
24500406	2475	Ma Y	High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.	Science translational medicine	2014	39
24819773	2475	Gupta AK	Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A.	PloS one	2014	37
25498219	2475	Grignani G	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.	The Lancet. Oncology	2015	30
26004684	2475	Han B	Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy.	Cancer cell	2015	20
26482279	2475	Motzer RJ	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.	The Lancet. Oncology	2015	57
26627594	2475	Qian P	The Dlk1-Gtl2 Locus Preserves LT-HSC Function by Inhibiting the PI3K-mTOR Pathway to Restrict Mitochondrial Metabolism.	Cell stem cell	2016	13
26794930	2475	Armstrong AJ	Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.	The Lancet. Oncology	2016	16
18782641	2641	Drucker DJ	Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.	Lancet	2008	200
19515413	2641	Buse JB	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).	Lancet	2009	299
20215461	2641	Buse JB	DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks.	Diabetes care	2010	56
20595511	2641	Wild D	Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.	Journal of nuclear medicine 	2010	42
20929995	2641	Best JH	Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.	Diabetes care	2011	55
21307137	2641	Blevins T	DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.	The Journal of clinical endocrinology and metabolism	2011	71
21920963	2641	Lønborg J	Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.	European heart journal	2012	70
22945360	2641	Meier JJ	GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.	Nature reviews. Endocrinology	2012	101
23141817	2641	Buse JB	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.	Lancet	2013	83
12522003	2736	Ludwiczek S	Cytokine-mediated regulation of iron transport in human monocytic cells.	Blood	2003	75
17222336	2736	Sharif O	Transcriptional profiling of the LPS induced NF-kappaB response in macrophages.	BMC immunology	2007	62
17599095	2736	Fernandes-Alnemri T	The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation.	Cell death and differentiation	2007	231
19427777	2736	Mullen A	Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages.	The Journal of nutritional biochemistry	2010	40
20622002	2736	Tili E	Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD.	Carcinogenesis	2010	57
21102562	2736	Akao Y	Microvesicle-mediated RNA molecule delivery system using monocytes/macrophages.	Molecular therapy 	2011	42
22258631	2736	Diehl P	Microparticles: major transport vehicles for distinct microRNAs in circulation.	Cardiovascular research	2012	86
22903635	2736	Freytes DO	Macrophages modulate the viability and growth of human mesenchymal stem cells.	Journal of cellular biochemistry	2013	28
18287102	2740	Runge S	Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain.	The Journal of biological chemistry	2008	101
19442172	2740	Cani PD	The role of the gut microbiota in energy metabolism and metabolic disease.	Current pharmaceutical design	2009	138
20225248	2740	Gupta NA	Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.	Hepatology	2010	75
20452396	2740	Erdogdu O	Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor.	Molecular and cellular endocrinology	2010	52
22236411	2740	Vilsbøll T	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.	BMJ	2012	118
23433305	2740	Wang B	Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.	Diabetes, obesity and metabolism	2013	28
23868944	2740	Woo JS	Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study.	Arteriosclerosis, thrombosis, and vascular biology	2013	28
23999198	2740	van Can J	Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.	International journal of obesity	2014	37
24467746	2740	Pyke C	GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.	Endocrinology	2014	53
24879836	2740	Wysham C	Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).	Diabetes care	2014	41
25071023	2740	van Bloemendaal L	GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans.	Diabetes	2014	35
10971201	2944	Hayes JD	Glutathione S-transferase polymorphisms and their biological consequences.	Pharmacology	2000	118
24518398	2944	Rossignol DA	Environmental toxicants and autism spectrum disorders: a systematic review.	Translational psychiatry	2014	59
12747895	3064	Bates G	Huntingtin aggregation and toxicity in Huntington's disease.	Lancet	2003	103
16141322	3064	Iwata A	Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation.	Proceedings of the National Academy of Sciences of the United States of America	2005	96
16832050	3064	Duennwald ML	Flanking sequences profoundly alter polyglutamine toxicity in yeast.	Proceedings of the National Academy of Sciences of the United States of America	2006	115
16965178	3064	Schwarz DS	Designing siRNA that distinguish between genes that differ by a single nucleotide.	PLoS genetics	2006	90
17041811	3064	Borrell-Pagès M	Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies.	Cellular and molecular life sciences 	2006	62
17118264	3064	Williams A	Aggregate-prone proteins are cleared from the cytosol by autophagy: therapeutic implications.	Current topics in developmental biology	2006	104
17240289	3064	Walker FO	Huntington's disease.	Lancet	2007	334
19361997	3064	Pfister EL	Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.	Current biology 	2009	80
19487684	3064	Nekooki-Machida Y	Distinct conformations of in vitro and in vivo amyloids of huntingtin-exon1 show different cytotoxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	78
21247881	3064	de Mezer M	Mutant CAG repeats of Huntingtin transcript fold into hairpins, form nuclear foci and are targets for RNA interference.	Nucleic acids research	2011	59
21971427	3064	Carroll JB	Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin.	Molecular therapy 	2011	69
21997870	3064	Shirendeb UP	Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease.	Human molecular genetics	2012	60
22735540	3064	Pieri L	Fibrillar α-synuclein and huntingtin exon 1 assemblies are toxic to the cells.	Biophysical journal	2012	52
27188817	3064	Bates GP	Huntington disease.	Nature reviews. Disease primers	2015	36
15743917	3106	Hung SI	HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.	Proceedings of the National Academy of Sciences of the United States of America	2005	122
18192896	3106	Lonjou C	A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.	Pharmacogenetics and genomics	2008	62
18256392	3106	Mallal S	HLA-B*5701 screening for hypersensitivity to abacavir.	The New England journal of medicine	2008	262
19696695	3106	Tassaneeyakul W	Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.	Pharmacogenetics and genomics	2009	51
21162721	3106	Harr T	Toxic epidermal necrolysis and Stevens-Johnson syndrome.	Orphanet journal of rare diseases	2010	60
22322005	3106	Wei CY	Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.	The Journal of allergy and clinical immunology	2012	37
12620891	3146	Park JS	Activation of gene expression in human neutrophils by high mobility group box 1 protein.	American journal of physiology. Cell physiology	2003	102
15502843	3146	Wang H	Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis.	Nature medicine	2004	249
16966386	3146	Yang D	High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin.	Journal of leukocyte biology	2007	116
18354232	3146	Youn JH	High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-alpha production in human monocytes.	Journal of immunology	2008	70
19564572	3146	Hreggvidsdottir HS	The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation.	Journal of leukocyte biology	2009	92
21871094	3146	Wähämaa H	High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts.	Arthritis research and therapy	2011	37
25636263	3146	Woolbright BL	Bile acid-induced necrosis in primary human hepatocytes and in patients with obstructive cholestasis.	Toxicology and applied pharmacology	2015	29
10631150	3162	Yamada N	Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema.	American journal of human genetics	2000	128
12130498	3162	Jeney V	Pro-oxidant and cytotoxic effects of circulating heme.	Blood	2002	116
15947085	3162	Hvidberg V	Identification of the receptor scavenging hemopexin-heme complexes.	Blood	2005	99
21992109	3162	Grochot-Przeczek A	Haem oxygenase-1: non-canonical roles in physiology and pathology.	Clinical science	2012	43
8152488	3375	Lorenzo A	Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.	Nature	1994	157
19244249	3375	Patil SM	Dynamic alpha-helix structure of micelle-bound human amylin.	The Journal of biological chemistry	2009	49
19346479	3375	Shim SH	Two-dimensional IR spectroscopy and isotope labeling defines the pathway of amyloid formation with residue-specific resolution.	Proceedings of the National Academy of Sciences of the United States of America	2009	86
20042670	3375	Gurlo T	Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway.	The American journal of pathology	2010	59
20182863	3375	Zraika S	Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence?	Diabetologia	2010	45
20609969	3375	Diamant M	Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.	Lancet	2010	88
21138825	3375	Buse JB	Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.	Annals of internal medicine	2011	93
21742788	3375	Westermark P	Islet amyloid polypeptide, islet amyloid, and diabetes mellitus.	Physiological reviews	2011	152
21942864	3375	Brender JR	Membrane disruption and early events in the aggregation of the diabetes related peptide IAPP from a molecular perspective.	Accounts of chemical research	2012	63
22683137	3375	Gallwitz B	Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.	Lancet	2012	34
24335073	3383	Lutty GA	Effects of diabetes on the eye.	Investigative ophthalmology and visual science	2013	26
3926894	3458	Shalaby MR	Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.	Journal of immunology	1985	172
9176497	3458	Döcke WD	Monocyte deactivation in septic patients: restoration by IFN-gamma treatment.	Nature medicine	1997	203
10725715	3458	Hwu P	Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.	Journal of immunology	2000	131
10905243	3458	Gereda JE	Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma.	Lancet	2000	90
11828007	3458	Gerosa F	Reciprocal activating interaction between natural killer cells and dendritic cells.	The Journal of experimental medicine	2002	218
12147537	3458	Adrie C	Successful cardiopulmonary resuscitation after cardiac arrest as a "sepsis-like" syndrome.	Circulation	2002	113
12239255	3458	Braun-Fahrländer C	Environmental exposure to endotoxin and its relation to asthma in school-age children.	The New England journal of medicine	2002	250
17916356	3458	Dolganiuc A	Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.	Gastroenterology	2007	65
18183290	3458	Kubica M	A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages.	PloS one	2008	91
19818653	3458	Feuerer M	How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets.	Immunity	2009	83
20015486	3458	Dowlati Y	A meta-analysis of cytokines in major depression.	Biological psychiatry	2010	516
20050849	3458	Schafer PH	Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.	British journal of pharmacology	2010	44
25644696	3458	Jiang W	Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease.	Scientific reports	2015	23
26949058	3458	Tomassen P	Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers.	The Journal of allergy and clinical immunology	2016	18
2065663	3552	Schreck R	Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1.	The EMBO journal	1991	506
2328723	3552	Rubartelli A	A novel secretory pathway for interleukin-1 beta, a protein lacking a signal sequence.	The EMBO journal	1990	154
2783334	3552	Waage A	The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome.	The Journal of experimental medicine	1989	198
8052854	3552	Kopp E	Inhibition of NF-kappa B by sodium salicylate and aspirin.	Science	1994	266
11581570	3552	Alexander C	Bacterial lipopolysaccharides and innate immunity.	Journal of endotoxin research	2001	149
19785746	3552	de Jager W	Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays.	BMC immunology	2009	70
19919576	3552	Fraser DA	C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production.	Journal of neurochemistry	2010	42
20061650	3552	McGeer EG	Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy.	Journal of Alzheimer's disease 	2010	80
22142165	3552	Rossol M	LPS-induced cytokine production in human monocytes and macrophages.	Critical reviews in immunology	2011	80
28099414	3552	Liddelow SA	Neurotoxic reactive astrocytes are induced by activated microglia.	Nature	2017	36
2835680	3553	Michie HR	Detection of circulating tumor necrosis factor after endotoxin administration.	The New England journal of medicine	1988	218
8910831	3553	Beck J	Periodontal disease and cardiovascular disease.	Journal of periodontology	1996	179
9531313	3553	Jovanovic DV	IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages.	Journal of immunology	1998	209
10430608	3553	Frantz S	Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium.	The Journal of clinical investigation	1999	106
14662866	3553	Cowland JB	Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha.	Journal of immunology	2003	75
15777250	3553	Nagatsu T	Inflammatory process in Parkinson's disease: role for cytokines.	Current pharmaceutical design	2005	70
16373510	3553	Gavrilin MA	Internalization and phagosome escape required for Francisella to induce human monocyte IL-1beta processing and release.	Proceedings of the National Academy of Sciences of the United States of America	2006	103
16740164	3553	Cone RA	Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission.	BMC infectious diseases	2006	63
17044947	3553	Cavaillon JM	Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis.	Critical care	2006	123
17383420	3553	Liebregts T	Immune activation in patients with irritable bowel syndrome.	Gastroenterology	2007	101
17636564	3553	Nesbitt A	Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.	Inflammatory bowel diseases	2007	60
18042719	3553	Tiemessen MM	CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages.	Proceedings of the National Academy of Sciences of the United States of America	2007	176
18504291	3553	Pott Godoy MC	Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease.	Brain 	2008	76
19104081	3553	Netea MG	Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages.	Blood	2009	195
20064793	3553	Samberg ME	Evaluation of silver nanoparticle toxicity in skin in vivo and keratinocytes in vitro.	Environmental health perspectives	2010	52
20127816	3553	Chakraborty S	Inflammasome signaling at the heart of central nervous system pathology.	Journal of neuroscience research	2010	45
20398664	3553	Ng J	Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome.	Gastroenterology	2010	54
21599903	3553	Brochu ME	Developmental regulation of the neuroinflammatory responses to LPS and/or hypoxia-ischemia between preterm and term neonates: An experimental study.	Journal of neuroinflammation	2011	36
21700772	3553	Wang JG	Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner.	Blood	2011	55
22071871	3553	Zunszain PA	Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis.	Neuropsychopharmacology 	2012	55
22081859	3553	He X	Multiwalled carbon nanotubes induce a fibrogenic response by stimulating reactive oxygen species production, activating NF-κB signaling, and promoting fibroblast-to-myofibroblast transformation.	Chemical research in toxicology	2011	45
23483986	3553	Dowling DJ	The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.	PloS one	2013	25
23630220	3553	Jaremka LM	Loneliness promotes inflammation during acute stress.	Psychological science	2013	28
23904163	3553	Farrera C	Macrophage clearance of neutrophil extracellular traps is a silent process.	Journal of immunology	2013	51
24198497	3553	Vandebriel RJ	A review of mammalian toxicity of ZnO nanoparticles.	Nanotechnology, science and applications	2012	41
27030597	3553	Masters SL	Familial autoinflammation with neutrophilic dermatosis reveals a regulatory mechanism of pyrin activation.	Science translational medicine	2016	15
3264384	3558	Rosenberg SA	Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.	The New England journal of medicine	1988	246
15128946	3558	Sundrud MS	Inhibition of primary human T cell proliferation by Helicobacter pylori vacuolating toxin (VacA) is independent of VacA effects on IL-2 secretion.	Proceedings of the National Academy of Sciences of the United States of America	2004	80
16224276	3558	Attia P	Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.	Journal of immunotherapy	2005	70
16308572	3558	Dannull J	Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.	The Journal of clinical investigation	2005	257
17025272	3558	Kreitman RJ	Immunotoxins for targeted cancer therapy.	The AAPS journal	2006	68
19001327	3558	Atkins MB	Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group.	Journal of clinical oncology 	2008	57
21631324	3558	Schwartzentruber DJ	gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.	The New England journal of medicine	2011	208
21940902	3558	Bajaj JS	Linkage of gut microbiome with cognition in hepatic encephalopathy.	American journal of physiology. Gastrointestinal and liver physiology	2012	69
22436957	3558	Tan J	Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.	JAMA	2012	99
24719405	3558	Bachanova V	Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.	Blood	2014	59
7836930	3569	van der Pouw Kraan TC	Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production.	The Journal of experimental medicine	1995	116
12626436	3569	Starkie R	Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans.	FASEB journal 	2003	96
15033490	3569	Wulster-Radcliffe MC	Adiponectin differentially regulates cytokines in porcine macrophages.	Biochemical and biophysical research communications	2004	95
15373964	3569	Dinarello CA	Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed.	Journal of endotoxin research	2004	79
15630704	3569	El-Hage N	Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat.	Glia	2005	96
15886319	3569	Kemna E	Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS.	Blood	2005	105
16864705	3569	Angelone DF	Innate immunity of the human newborn is polarized toward a high ratio of IL-6/TNF-alpha production in vitro and in vivo.	Pediatric research	2006	61
17090751	3569	Creely SJ	Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes.	American journal of physiology. Endocrinology and metabolism	2007	160
19073750	3569	Miller GE	Chronic interpersonal stress predicts activation of pro- and anti-inflammatory signaling pathways 6 months later.	Psychosomatic medicine	2009	53
19376240	3569	Eisenberger NI	An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences.	NeuroImage	2009	61
19794059	3569	Mehta NN	Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.	Diabetes	2010	82
19828697	3569	Funderburg NT	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation.	Blood	2010	89
20043983	3569	Eisenberger NI	Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood.	Brain, behavior, and immunity	2010	78
20303729	3569	Laugerette F	Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation.	The Journal of nutritional biochemistry	2011	46
20629534	3569	Cassol E	Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.	The Journal of infectious diseases	2010	73
21726511	3569	Sandler NG	Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection.	Gastroenterology	2011	90
22184247	3569	Gibbs JE	The nuclear receptor REV-ERBα mediates circadian regulation of innate immunity through selective regulation of inflammatory cytokines.	Proceedings of the National Academy of Sciences of the United States of America	2012	108
23065151	3569	Funderburg NT	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome.	Blood	2012	73
23071313	3569	Rossato M	IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes.	Proceedings of the National Academy of Sciences of the United States of America	2012	39
23160966	3569	Piya MK	Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin.	The Journal of endocrinology	2013	37
24828436	3569	Bala S	Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals.	PloS one	2014	38
25317870	3569	Maude SL	Chimeric antigen receptor T cells for sustained remissions in leukemia.	The New England journal of medicine	2014	447
3260265	3576	Matsushima K	Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor.	The Journal of experimental medicine	1988	186
7729872	3576	Sharma SA	Interleukin-8 response of gastric epithelial cell lines to Helicobacter pylori stimulation in vitro.	Infection and immunity	1995	115
10823949	3576	Nanthakumar NN	Inflammation in the developing human intestine: A possible pathophysiologic contribution to necrotizing enterocolitis.	Proceedings of the National Academy of Sciences of the United States of America	2000	94
15337792	3576	Cosio BG	Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.	The Journal of experimental medicine	2004	85
17141434	3576	Pulskamp K	Carbon nanotubes show no sign of acute toxicity but induce intracellular reactive oxygen species in dependence on contaminants.	Toxicology letters	2007	105
18390664	3576	Gelber SE	Functional and phylogenetic characterization of Vaginolysin, the human-specific cytolysin from Gardnerella vaginalis.	Journal of bacteriology	2008	62
20049649	3576	Bucki R	Cathelicidin LL-37: a multitask antimicrobial peptide.	Archivum immunologiae et therapiae experimentalis	2010	46
24190997	3576	Batchelor TT	Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.	Proceedings of the National Academy of Sciences of the United States of America	2013	79
11342442	3586	Cooper MA	Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.	Blood	2001	248
12606496	3630	Robertson RP	Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection.	Diabetes	2003	124
15983207	3630	Ryan EA	Five-year follow-up after clinical islet transplantation.	Diabetes	2005	338
16230722	3630	Heine RJ	Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.	Annals of internal medicine	2005	142
18158075	3630	Barnett AH	Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.	Clinical therapeutics	2007	62
18312311	3630	James WP	The epidemiology of obesity: the size of the problem.	Journal of internal medicine	2008	137
19196887	3630	Bunck MC	One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.	Diabetes care	2009	105
20079586	3630	Wulan SN	Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians.	Maturitas	2010	40
20130101	3630	Ruhlman T	The role of heterologous chloroplast sequence elements in transgene integration and expression.	Plant physiology	2010	58
20361178	3630	DeFronzo RA	Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009.	Diabetologia	2010	131
20724178	3630	Liu M	Proinsulin misfolding and diabetes: mutant INS gene-induced diabetes of youth.	Trends in endocrinology and metabolism	2010	43
21050286	3630	Caesar R	Effects of gut microbiota on obesity and atherosclerosis via modulation of inflammation and lipid metabolism.	Journal of internal medicine	2010	42
22326434	3630	Cusi K	Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.	Gastroenterology	2012	112
23099275	3630	Kwon KC	Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells.	Advanced drug delivery reviews	2013	35
24316517	3630	Vrieze A	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.	Journal of hepatology	2014	48
7542010	3929	Ulevitch RJ	Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin.	Annual review of immunology	1995	264
7681988	3929	Pugin J	Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14.	Proceedings of the National Academy of Sciences of the United States of America	1993	151
18575590	3929	Ancuta P	Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients.	PloS one	2008	185
18052394	4051	Guengerich FP	Cytochrome p450 and chemical toxicology.	Chemical research in toxicology	2008	210
2161532	4353	Falk RJ	Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.	Proceedings of the National Academy of Sciences of the United States of America	1990	218
21771337	4353	O'Hanlon DE	In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide.	BMC infectious diseases	2011	57
22647055	4353	Zhao H	Protective role of 1,25(OH)2 vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice.	BMC gastroenterology	2012	36
22810731	4353	Marcinkiewicz J	Taurine and inflammatory diseases.	Amino acids	2014	28
15985429	4780	Hong F	Specific patterns of electrophile adduction trigger Keap1 ubiquitination and Nrf2 activation.	The Journal of biological chemistry	2005	101
17145701	4780	Zhang DD	Mechanistic studies of the Nrf2-Keap1 signaling pathway.	Drug metabolism reviews	2006	222
18083283	4780	Copple IM	The Nrf2-Keap1 defence pathway: role in protection against drug-induced toxicity.	Toxicology	2008	57
18164232	4780	Osburn WO	Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults.	Mutation research	2008	101
18838122	4780	Lau A	Dual roles of Nrf2 in cancer.	Pharmacological research	2008	168
20530669	4780	Jiang T	High levels of Nrf2 determine chemoresistance in type II endometrial cancer.	Cancer research	2010	72
23311665	4780	Brüne B	Redox control of inflammation in macrophages.	Antioxidants and redox signaling	2013	47
23492819	4780	Singh B	MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis.	Carcinogenesis	2013	30
25912479	4780	Schäfer M	Nrf2--A regulator of keratinocyte redox signaling.	Free radical biology and medicine	2015	15
9841923	4790	Kirschning CJ	Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide.	The Journal of experimental medicine	1998	126
10557090	4790	Plummer SM	Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex.	Oncogene	1999	96
12820969	4790	Saccani S	Modulation of NF-kappaB activity by exchange of dimers.	Molecular cell	2003	88
15578112	4790	Lehrke M	An inflammatory cascade leading to hyperresistinemia in humans.	PLoS medicine	2004	87
16595631	4790	Schreiber J	Coordinated binding of NF-kappaB family members in the response of human cells to lipopolysaccharide.	Proceedings of the National Academy of Sciences of the United States of America	2006	65
18566250	4790	Kravchenko VV	Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule.	Science	2008	65
20041225	4790	Gao X	Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function.	PLoS pathogens	2009	59
20231449	4790	Polyak SJ	Identification of hepatoprotective flavonolignans from silymarin.	Proceedings of the National Academy of Sciences of the United States of America	2010	50
24846769	4790	Ghosh S	Elevated muscle TLR4 expression and metabolic endotoxemia in human aging.	The journals of gerontology. Series A, Biological sciences and medical sciences	2015	21
14669979	4843	Kleinert H	Regulation of the expression of inducible nitric oxide synthase.	Biological chemistry	2003	89
20423716	4843	Saito C	c-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity.	Toxicology and applied pharmacology	2010	70
8037844	5091	Safe SH	Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment.	Critical reviews in toxicology	1994	179
19320182	5091	Patterson DG Jr	Levels in the U.S. population of those persistent organic pollutants (2003-2004) included in the Stockholm Convention or in other long range transboundary air pollution agreements.	Environmental science and technology	2009	51
26719230	5091	Zalcman G	Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.	Lancet	2016	34
18577180	5243	Dunkel N	Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains.	Molecular microbiology	2008	77
19117944	5243	Raj DK	Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione.	The Journal of biological chemistry	2009	53
21967057	5243	Sharom FJ	The P-glycoprotein multidrug transporter.	Essays in biochemistry	2011	64
19798427	6279	Oldani A	Helicobacter pylori counteracts the apoptotic action of its VacA toxin by injecting the CagA protein into gastric epithelial cells.	PLoS pathogens	2009	50
12042811	6622	Xu J	Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.	Nature medicine	2002	141
12062037	6622	Giasson BI	Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.	Neuron	2002	239
12217698	6622	Hoyer W	Dependence of alpha-synuclein aggregate morphology on solution conditions.	Journal of molecular biology	2002	91
15590933	6622	Yavich L	Role of alpha-synuclein in presynaptic dopamine recruitment.	The Journal of neuroscience 	2004	76
17166628	6622	Klegeris A	Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia.	Neurobiology of aging	2008	52
18291704	6622	Lee HJ	Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein.	The international journal of biochemistry and cell biology	2008	130
18511942	6622	Ehrnhoefer DE	EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers.	Nature structural and molecular biology	2008	201
18704197	6622	Lo Bianco C	Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease.	The Journal of clinical investigation	2008	60
18769546	6622	Tsigelny IF	Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.	PloS one	2008	69
19074459	6622	Azeredo da Silveira S	Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease.	Human molecular genetics	2009	55
19436756	6622	Xilouri M	Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy.	PloS one	2009	90
19855133	6622	Chen L	Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation.	The Journal of clinical investigation	2009	54
20392839	6622	Thayanidhi N	Alpha-synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by antagonizing ER/Golgi SNAREs.	Molecular biology of the cell	2010	73
20534649	6622	Garcia-Reitböck P	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.	Brain 	2010	56
20599975	6622	Wills J	Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia.	Experimental neurology	2010	45
20696318	6622	Oueslati A	Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies.	Progress in brain research	2010	67
22094370	6622	Jain S	Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.	Neurobiology of disease	2012	35
23526723	6622	Lesage S	G51D α-synuclein mutation causes a novel parkinsonian-pyramidal syndrome.	Annals of neurology	2013	96
25352339	6622	Moussaud S	Alpha-synuclein and tau: teammates in neurodegeneration?	Molecular neurodegeneration	2014	20
25676491	6622	Sengupta U	Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.	Biological psychiatry	2015	20
26352473	6622	Rodriguez JA	Structure of the toxic core of α-synuclein from invisible crystals.	Nature	2015	44
10195180	6647	Williamson TL	Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons.	Nature neuroscience	1999	122
12754496	6647	Elam JS	Amyloid-like filaments and water-filled nanotubes formed by SOD1 mutant proteins linked to familial ALS.	Nature structural biology	2003	87
15326189	6647	Arnesano F	The unusually stable quaternary structure of human Cu,Zn-superoxide dismutase 1 is controlled by both metal occupancy and disulfide status.	The Journal of biological chemistry	2004	73
18666828	6647	Wang Q	Protein aggregation and protein instability govern familial amyotrophic lateral sclerosis patient survival.	PLoS biology	2008	53
19041780	6647	Di Giorgio FP	Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation.	Cell stem cell	2008	148
19477268	6647	Miao L	Regulation of superoxide dismutase genes: implications in disease.	Free radical biology and medicine	2009	98
19672969	6647	Zhao W	Extracellular mutant SOD1 induces microglial-mediated motoneuron injury.	Glia	2010	59
20953194	6647	Bosco DA	Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.	Nature neuroscience	2010	181
21832997	6647	Haidet-Phillips AM	Astrocytes from familial and sporadic ALS patients are toxic to motor neurons.	Nature biotechnology	2011	186
21908873	6647	Ferraiuolo L	Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis.	Brain 	2011	37
22219285	6647	Magrané J	Mitochondrial dynamics and bioenergetic dysfunction is associated with synaptic alterations in mutant SOD1 motor neurons.	The Journal of neuroscience 	2012	41
22416121	6647	Guareschi S	An over-oxidized form of superoxide dismutase found in sporadic amyotrophic lateral sclerosis with bulbar onset shares a toxic mechanism with mutant SOD1.	Proceedings of the National Academy of Sciences of the United States of America	2012	52
22431618	6647	Brotherton TE	Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALS.	Proceedings of the National Academy of Sciences of the United States of America	2012	31
22967507	6647	Weisberg SJ	Compartmentalization of superoxide dismutase 1 (SOD1G93A) aggregates determines their toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2012	37
24379756	6647	Rotunno MS	An emerging role for misfolded wild-type SOD1 in sporadic ALS pathogenesis.	Frontiers in cellular neuroscience	2013	36
26657039	6647	Kaur SJ	Mutant SOD1 mediated pathogenesis of Amyotrophic Lateral Sclerosis.	Gene	2016	15
11208096	7018	Fujimoto LM	Actin assembly plays a variable, but not obligatory role in receptor-mediated endocytosis in mammalian cells.	Traffic	2000	93
14980223	7018	Cheng Y	Structure of the human transferrin receptor-transferrin complex.	Cell	2004	105
19484405	7018	Anderson GJ	Mammalian iron transport.	Cellular and molecular life sciences 	2009	52
21855608	7018	Brissot P	Non-transferrin bound iron: a key role in iron overload and iron toxicity.	Biochimica et biophysica acta	2012	71
24573305	7018	Tortorella S	Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.	The Journal of membrane biology	2014	25
9751057	7097	Yang RB	Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling.	Nature	1998	195
10384090	7097	Yoshimura A	Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2.	Journal of immunology	1999	258
10426996	7097	Aliprantis AO	Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2.	Science	1999	351
10452971	7097	Hirschfeld M	Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2.	Journal of immunology	1999	164
11035751	7097	Lorenz E	A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection.	Infection and immunity	2000	101
12538701	7097	Melmed G	Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut.	Journal of immunology	2003	111
15007351	7097	Eder W	Toll-like receptor 2 as a major gene for asthma in children of European farmers.	The Journal of allergy and clinical immunology	2004	88
18201283	7097	Herbst-Kralovetz MM	Quantification and comparison of toll-like receptor expression and responsiveness in primary and immortalized human female lower genital tract epithelia.	American journal of reproductive immunology	2008	52
18458151	7097	Nilsen NJ	Cellular trafficking of lipoteichoic acid and Toll-like receptor 2 in relation to signaling: role of CD14 and CD36.	Journal of leukocyte biology	2008	50
19735274	7097	Sjögren YM	Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses.	Clinical and experimental allergy 	2009	63
10196138	7099	Chow JC	Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction.	The Journal of biological chemistry	1999	332
11921384	7099	Hagberg H	Models of white matter injury: comparison of infectious, hypoxic-ischemic, and excitotoxic insults.	Mental retardation and developmental disabilities research reviews	2002	94
12045108	7099	Raetz CR	Lipopolysaccharide endotoxins.	Annual review of biochemistry	2002	920
12324469	7099	Latz E	Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction.	The Journal of biological chemistry	2002	126
12717385	7099	Paik YH	Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.	Hepatology	2003	157
14600154	7099	Guillot L	Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4.	The Journal of biological chemistry	2004	85
15608698	7099	Miller SI	LPS, TLR4 and infectious disease diversity.	Nature reviews. Microbiology	2005	238
16953973	7099	Trent MS	Diversity of endotoxin and its impact on pathogenesis.	Journal of endotoxin research	2006	85
17384648	7099	Clark SR	Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood.	Nature medicine	2007	334
19318560	7099	Szczepanski MJ	Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.	Cancer research	2009	59
19661804	7099	Tidswell M	Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.	Critical care medicine	2010	43
20592272	7099	Manco M	Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk.	Endocrine reviews	2010	83
22451944	7099	Schroder K	Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages.	Proceedings of the National Academy of Sciences of the United States of America	2012	57
22777111	7099	Salomao R	Bacterial sensing, cell signaling, and modulation of the immune response during sepsis.	Shock	2012	49
23322736	7099	Michaud JP	Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology.	Proceedings of the National Academy of Sciences of the United States of America	2013	40
24307174	7099	Guijarro-Muñoz I	Lipopolysaccharide activates Toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway and proinflammatory response in human pericytes.	The Journal of biological chemistry	2014	27
24766885	7099	Tan Y	A cross-disciplinary perspective on the innate immune responses to bacterial lipopolysaccharide.	Molecular cell	2014	28
26133659	7099	Boutagy NE	Metabolic endotoxemia with obesity: Is it real and is it relevant?	Biochimie	2016	20
8119492	7124	Rietschel ET	Bacterial endotoxin: molecular relationships of structure to activity and function.	FASEB journal 	1994	266
8198398	7124	Tracey KJ	Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.	Annual review of medicine	1994	148
8637514	7124	Fisher CJ Jr	Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.	The New England journal of medicine	1996	158
9219699	7124	Moreland LW	Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.	The New England journal of medicine	1997	180
10449104	7124	-	TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.	Neurology	1999	134
10839541	7124	Borovikova LV	Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin.	Nature	2000	542
11792859	7124	Angelini G	Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation.	Proceedings of the National Academy of Sciences of the United States of America	2002	83
11907116	7124	Belge KU	The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.	Journal of immunology	2002	167
15044327	7124	Hagemann T	Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.	Carcinogenesis	2004	92
15383597	7124	Levy O	Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.	Journal of immunology	2004	99
17660390	7124	Rajesh M	CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.	American journal of physiology. Heart and circulatory physiology	2007	70
20876255	7124	Libutti SK	Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.	Clinical cancer research 	2010	91
21245297	7124	Hess A	Blockade of TNF-α rapidly inhibits pain responses in the central nervous system.	Proceedings of the National Academy of Sciences of the United States of America	2011	50
21569482	7124	Danchuk S	Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor-α-induced protein 6.	Stem cell research and therapy	2011	54
21969554	7124	Rajaram MV	Mycobacterium tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-activated protein kinase 2 (MK2) and microRNA miR-125b.	Proceedings of the National Academy of Sciences of the United States of America	2011	69
22884417	7124	Ganz PA	Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?	Brain, behavior, and immunity	2013	44
22955726	7124	Griep LM	BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function.	Biomedical microdevices	2013	49
1672732	7157	Bressac B	Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa.	Nature	1991	191
8832894	7157	Denissenko MF	Preferential formation of benzoapyrene adducts at lung cancer mutational hotspots in P53.	Science	1996	229
12821280	7157	Ichihashi M	UV-induced skin damage.	Toxicology	2003	95
15054096	7157	Wang S	Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways.	The Journal of biological chemistry	2004	88
17638885	7157	Buzzai M	Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth.	Cancer research	2007	296
18454141	7157	Tasdemir E	Regulation of autophagy by cytoplasmic p53.	Nature cell biology	2008	313
21779517	7157	Rufini A	p73 in Cancer.	Genes and cancer	2011	39
22551203	7157	Intarasunanont P	Effects of arsenic exposure on DNA methylation in cord blood samples from newborn babies and in a human lymphoblast cell line.	Environmental health 	2012	38
24721780	7157	Zhang A	Role of the lncRNA-p53 regulatory network in cancer.	Journal of molecular cell biology	2014	22
26032560	7157	Amelio I	The p53 family and the hypoxia-inducible factors (HIFs): determinants of cancer progression.	Trends in biochemical sciences	2015	15
27580721	7157	Zhang F	Molecular signatures associated with ZIKV exposure in human cortical neural progenitors.	Nucleic acids research	2016	20
10688871	7422	Kerbel RS	Tumor angiogenesis: past, present and the near future.	Carcinogenesis	2000	118
12890841	7422	Yang JC	A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.	The New England journal of medicine	2003	446
16376330	7422	Folkman J	Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.	Experimental cell research	2006	116
17167137	7422	Sandler A	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.	The New England journal of medicine	2006	1175
19150949	7422	Izzedine H	Management of hypertension in angiogenesis inhibitor-treated patients.	Annals of oncology 	2009	57
20351338	7422	Maitland ML	Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.	Journal of the National Cancer Institute	2010	53
21167939	7422	Fidler IJ	The role of the organ microenvironment in brain metastasis.	Seminars in cancer biology	2011	63
22056247	7422	Rini BI	Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.	Lancet	2011	303
22204725	7422	Perren TJ	A phase 3 trial of bevacizumab in ovarian cancer.	The New England journal of medicine	2011	299
22910841	7422	Agulnik M	An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas.	Annals of oncology 	2013	49
23589874	7422	Lin VS	Cell-trappable fluorescent probes for endogenous hydrogen sulfide signaling and imaging H2O2-dependent H2S production.	Proceedings of the National Academy of Sciences of the United States of America	2013	33
24552320	7422	Tewari KS	Improved survival with bevacizumab in advanced cervical cancer.	The New England journal of medicine	2014	139
26179201	7422	Valle JW	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.	The Lancet. Oncology	2015	20
26321262	7422	Chua MLK	Nasopharyngeal carcinoma.	Lancet	2016	42
19528207	9468	Harris AM	Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh.	Infection and immunity	2009	47
21415489	9468	Sanchez J	Cholera toxin - a foe &amp;amp; a friend.	The Indian journal of medical research	2011	42
15016372	10242	Herwald H	M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage.	Cell	2004	77
18381563	10242	Kuryatov A	Roles of accessory subunits in alpha4beta2(*) nicotinic receptors.	Molecular pharmacology	2008	84
21464088	10242	Li J	The Agr-like quorum-sensing system regulates sporulation and production of enterotoxin and beta2 toxin by Clostridium perfringens type A non-food-borne human gastrointestinal disease strain F5603.	Infection and immunity	2011	35
11058605	10392	Inohara N	Human Nod1 confers responsiveness to bacterial lipopolysaccharides.	The Journal of biological chemistry	2001	87
12791997	10392	Girardin SE	Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan.	Science	2003	333
16299289	10392	Tada H	Synergistic effect of Nod1 and Nod2 agonists with toll-like receptor agonists on human dendritic cells to generate interleukin-12 and T helper type 1 cells.	Infection and immunity	2005	96
14699511	10599	Kullak-Ublick GA	Enterohepatic bile salt transporters in normal physiology and liver disease.	Gastroenterology	2004	85
21854228	10599	Obaidat A	The expression and function of organic anion transporting polypeptides in normal tissues and in cancer.	Annual review of pharmacology and toxicology	2012	47
22232210	10599	van de Steeg E	Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.	The Journal of clinical investigation	2012	42
18802454	23435	Rutherford NJ	Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis.	PLoS genetics	2008	151
19383787	23435	Zhang YJ	Aberrant cleavage of TDP-43 enhances aggregation and cellular toxicity.	Proceedings of the National Academy of Sciences of the United States of America	2009	158
19465477	23435	Johnson BS	TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity.	The Journal of biological chemistry	2009	182
19808791	23435	Pesiridis GS	Mutations in TDP-43 link glycine-rich domain functions to amyotrophic lateral sclerosis.	Human molecular genetics	2009	86
19833869	23435	Wegorzewska I	TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration.	Proceedings of the National Academy of Sciences of the United States of America	2009	190
19959528	23435	Kabashi E	Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo.	Human molecular genetics	2010	120
20621187	23435	Stallings NR	Progressive motor weakness in transgenic mice expressing human TDP-43.	Neurobiology of disease	2010	58
22029574	23435	Xu YF	Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice.	Molecular neurodegeneration	2011	44
22127299	23435	Lee EB	Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration.	Nature reviews. Neuroscience	2011	149
23587065	23435	Bentmann E	Stress granules in neurodegeneration--lessons learnt from TAR DNA binding protein of 43 kDa and fused in sarcoma.	The FEBS journal	2013	44
23900071	23435	Janssens J	Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.	Human molecular genetics	2013	33
10359581	23643	Shimazu R	MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.	The Journal of experimental medicine	1999	396
11123299	23643	Visintin A	Regulation of Toll-like receptors in human monocytes and dendritic cells.	Journal of immunology	2001	122
11466383	23643	Abreu MT	Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide.	Journal of immunology	2001	146
12594207	23643	Schröder NW	Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.	The Journal of biological chemistry	2003	134
12807870	23643	Smith MF Jr	Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for Helicobacter pylori-induced NF-kappa B activation and chemokine expression by epithelial cells.	The Journal of biological chemistry	2003	108
14609719	23643	Fujihara M	Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex.	Pharmacology and therapeutics	2003	91
15010525	23643	Gioannini TL	Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations.	Proceedings of the National Academy of Sciences of the United States of America	2004	91
16709849	23643	Cole LE	Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity.	Journal of immunology	2006	70
17569869	23643	Ohto U	Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa.	Science	2007	131
24911279	26040	Derycke L	Mixed T helper cell signatures in chronic rhinosinusitis with and without polyps.	PloS one	2014	21
22133721	29126	Amarnath S	The PDL1-PD1 axis converts human TH1 cells into regulatory T cells.	Science translational medicine	2011	74
22658128	29126	Brahmer JR	Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.	The New England journal of medicine	2012	1346
25482239	29126	Ansell SM	PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.	The New England journal of medicine	2015	397
26325035	29126	Chen L	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.	The Journal of clinical investigation	2015	73
27157491	29126	Muro K	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.	The Lancet. Oncology	2016	36
28081914	29126	Plimack ER	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.	The Lancet. Oncology	2017	7
2644022	53947	Karmali MA	Infection by verocytotoxin-producing Escherichia coli.	Clinical microbiology reviews	1989	345
2154550	54205	Schapira AH	Mitochondrial complex I deficiency in Parkinson's disease.	Journal of neurochemistry	1990	231
2557792	54205	Parker WD Jr	Abnormalities of the electron transport chain in idiopathic Parkinson's disease.	Annals of neurology	1989	164
12606514	54205	Maedler K	Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function.	Diabetes	2003	113
15922971	54205	Moghimi SM	A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy.	Molecular therapy 	2005	127
16276417	54205	Genestier AL	Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils.	The Journal of clinical investigation	2005	87
19001420	54205	Timmer AM	Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis.	The Journal of biological chemistry	2009	49
23460563	54205	Bai X	Ketamine enhances human neural stem cell proliferation and induces neuronal apoptosis via reactive oxygen species-mediated mitochondrial pathway.	Anesthesia and analgesia	2013	28
24942732	54205	Luth ES	Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction.	The Journal of biological chemistry	2014	24
16330770	55244	Otsuka M	A human transporter protein that mediates the final excretion step for toxic organic cations.	Proceedings of the National Academy of Sciences of the United States of America	2005	94
19228809	55244	Becker ML	Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study.	Diabetes	2009	57
21103969	55244	Nies AT	Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy.	Handbook of experimental pharmacology	2011	75
21241070	55244	Graham GG	Clinical pharmacokinetics of metformin.	Clinical pharmacokinetics	2011	106
17442855	114548	Lamkanfi M	Caspase-1 inflammasomes in infection and inflammation.	Journal of leukocyte biology	2007	60
17763411	114548	Gattorno M	Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations.	Arthritis and rheumatism	2007	65
18005730	114548	Willingham SB	Microbial pathogen-induced necrotic cell death mediated by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC.	Cell host and microbe	2007	105
19805629	114548	Lamkanfi M	Glyburide inhibits the Cryopyrin/Nalp3 inflammasome.	The Journal of cell biology	2009	151
19826485	114548	Craven RR	Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells.	PloS one	2009	115
20008285	114548	Meixenberger K	Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3.	Journal of immunology	2010	65
20668705	114548	Rajamäki K	Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation.	PloS one	2010	147
22461501	114548	Shenoy AR	GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals.	Science	2012	88
22523386	114548	Benoit ME	Complement protein C1q directs macrophage polarization and limits inflammasome activity during the uptake of apoptotic cells.	Journal of immunology	2012	49
22698681	114548	Kauppinen A	Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells--implications for age-related macular degeneration (AMD).	Immunology letters	2012	45
23530046	114548	Rajamäki K	Extracellular acidosis is a novel danger signal alerting innate immunity via the NLRP3 inflammasome.	The Journal of biological chemistry	2013	40
23737748	114548	McAuley JL	Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease.	PLoS pathogens	2013	45
24623131	114548	Ghonime MG	Inflammasome priming by lipopolysaccharide is dependent upon ERK signaling and proteasome function.	Journal of immunology	2014	28
25330206	114548	Abais JM	Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector?	Antioxidants and redox signaling	2015	24
25917098	114548	Sokolowska M	Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages.	Journal of immunology	2015	21
25993444	114548	Schaale K	Strain- and host species-specific inflammasome activation, IL-1β release, and cell death in macrophages infected with uropathogenic Escherichia coli.	Mucosal immunology	2016	11
27006445	114548	Xi H	Caspase-1 Inflammasome Activation Mediates Homocysteine-Induced Pyrop-Apoptosis in Endothelial Cells.	Circulation research	2016	11
27037191	114548	Gaidt MM	Human Monocytes Engage an Alternative Inflammasome Pathway.	Immunity	2016	25
27669650	114548	He Y	Mechanism and Regulation of NLRP3 Inflammasome Activation.	Trends in biochemical sciences	2016	22
16807400	146802	Masuda S	Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2.	Journal of the American Society of Nephrology 	2006	67
17509534	146802	Tanihara Y	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters.	Biochemical pharmacology	2007	70
23267855	146802	Stocker SL	The effect of novel promoter variants in MATE1 and MATE2 on the pharmacokinetics and pharmacodynamics of metformin.	Clinical pharmacology and therapeutics	2013	28
12872135	148022	Hoebe K	Identification of Lps2 as a key transducer of MyD88-independent TIR signalling.	Nature	2003	339
19781994	148022	Biswas SK	Endotoxin tolerance: new mechanisms, molecules and clinical significance.	Trends in immunology	2009	275
21298114	148022	Coler RN	Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant.	PloS one	2011	94
22474023	148022	Figueroa L	The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF.	Journal of immunology	2012	40
23423380	203228	Reddy K	The disease-associated r(GGGGCC)n repeat from the C9orf72 gene forms tract length-dependent uni- and multimolecular RNA G-quadruplex structures.	The Journal of biological chemistry	2013	80
24371143	203228	Zamiri B	TMPyP4 porphyrin distorts RNA G-quadruplex structures of the disease-associated r(GGGGCC)n repeat of the C9orf72 gene and blocks interaction of RNA-binding proteins.	The Journal of biological chemistry	2014	29
24379375	203228	Meyer K	Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS.	Proceedings of the National Academy of Sciences of the United States of America	2014	64
24549040	203228	Farg MA	C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking.	Human molecular genetics	2014	68
24806409	203228	Liu EY	C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD.	Acta neuropathologica	2014	39
25132468	203228	Su Z	Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS.	Neuron	2014	53
25398948	203228	Yamakawa M	Characterization of the dipeptide repeat protein in the molecular pathogenesis of c9FTD/ALS.	Human molecular genetics	2015	25
25521377	203228	Wen X	Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death.	Neuron	2014	61
26481318	203228	Gijselinck I	The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter.	Molecular psychiatry	2016	16
16635908	100506658	Drago S	Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines.	Scandinavian journal of gastroenterology	2006	62
16644703	100506658	Sapone A	Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives.	Diabetes	2006	81
21294650	100506658	Carrano A	Amyloid Beta induces oxidative stress-mediated blood-brain barrier changes in capillary amyloid angiopathy.	Antioxidants and redox signaling	2011	45
